AU2003247841A1 - Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes - Google Patents

Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes

Info

Publication number
AU2003247841A1
AU2003247841A1 AU2003247841A AU2003247841A AU2003247841A1 AU 2003247841 A1 AU2003247841 A1 AU 2003247841A1 AU 2003247841 A AU2003247841 A AU 2003247841A AU 2003247841 A AU2003247841 A AU 2003247841A AU 2003247841 A1 AU2003247841 A1 AU 2003247841A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
directed against
antibodies directed
hcv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003247841A
Other languages
English (en)
Other versions
AU2003247841A8 (en
Inventor
Steven K. H. Foung
Zhen-Yong Keck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2003247841A1 publication Critical patent/AU2003247841A1/en
Publication of AU2003247841A8 publication Critical patent/AU2003247841A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003247841A 2002-07-02 2003-06-27 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes Abandoned AU2003247841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/188,608 US20030180284A1 (en) 1998-11-05 2002-07-02 Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US10/188,608 2002-07-02
PCT/US2003/020580 WO2004005316A2 (en) 2002-07-02 2003-06-27 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes

Publications (2)

Publication Number Publication Date
AU2003247841A1 true AU2003247841A1 (en) 2004-01-23
AU2003247841A8 AU2003247841A8 (en) 2004-01-23

Family

ID=30114012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003247841A Abandoned AU2003247841A1 (en) 2002-07-02 2003-06-27 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes

Country Status (5)

Country Link
US (1) US20030180284A1 (enExample)
EP (1) EP1572721A4 (enExample)
JP (1) JP2006504645A (enExample)
AU (1) AU2003247841A1 (enExample)
WO (1) WO2004005316A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
DE60231475D1 (de) * 2001-01-12 2009-04-23 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
EP2004684A4 (en) * 2006-03-22 2009-05-06 Genimmune N V THE HEPATITIS C-VIRUS NEUTRALIZING ANTIBODIES
MX2009008706A (es) 2007-02-21 2009-09-14 Univ Massachusetts Anticuerpos humanos contra el virus de la hepatitis c (hcv) y usos de los mismos.
JPWO2009014216A1 (ja) 2007-07-25 2010-10-07 国立感染症研究所長 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体およびその用途
WO2010047829A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Mutant hepatitis c virus e2 polypeptides for hcv treatment
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
MX2016011885A (es) * 2014-03-20 2016-12-02 Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c.
CN106749645B (zh) * 2016-11-14 2019-12-03 广州泰诺迪生物科技有限公司 一种全人源抗丙型肝炎病毒的中和抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002190A1 (en) * 1991-07-15 1993-02-04 The Wellcome Foundation Limited Production of antibodies
DE69232859T2 (de) * 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
AU2001292667A1 (en) * 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof

Also Published As

Publication number Publication date
WO2004005316A3 (en) 2005-08-04
EP1572721A4 (en) 2009-05-27
AU2003247841A8 (en) 2004-01-23
JP2006504645A (ja) 2006-02-09
EP1572721A2 (en) 2005-09-14
US20030180284A1 (en) 2003-09-25
WO2004005316A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2002310325A1 (en) Use of ozone for the prevention of infection caused by medical devices
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
AU2002347458A1 (en) Device for intracorporeal and extracorporeal purification
EP1446121A4 (en) DI-INDOLYLMETHANE FOR THE TREATMENT OF INFECTIONS BY HUMAN PAPILLOMAVIRUS
AU2003247841A1 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
AU2002246545A1 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
AU2002356509A1 (en) Diagnosis of flavivirus infection
AU2003260778A1 (en) Treatment of pipes
AU2002368331A1 (en) Passive hyperimmune antibody therapy in the treatment of anthrax
AU2001259507A1 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
EP1482955A4 (en) PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES AND OTHER DISEASES USING IMMUNO EFFECTOR COMPOUNDS
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
AU2003238175A1 (en) Treatment of serious infections and septic shock
AU2002367861A1 (en) Prevention and treatment of streptococcal and staphylococcal infection
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2003304316A8 (en) Compounds and methods for the treatment and prevention of bacterial infection
AU2001282277A1 (en) Treatment of mycobacterial infection
AU2003299493A1 (en) Compositions and methods for the treatment of hepatitis c virus infection
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans
AU2003255866A8 (en) Gp41 epitope and uses thereof for the treatment of hiv infections
IL151776A0 (en) Chimeric proteins for prevention and treatment of hiv infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase